Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.50 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12064447 | 0.87 | NTRK1 (0.47) | GSK3BGRM4 | |
| SCHEMBL27909188 | 0.80 | GSK3B (0.54) | GSK3BMAP2K4DYRK1A | |
| SCHEMBL8348438 | 0.77 | KIF11 (0.47) | GSK3BMAP2K4KIF11FGFR1DYRK1A | |
| SCHEMBL14942621 | 0.77 | ITK (0.47) | GSK3BMAP2K4KIF11DYRK1A | |
| SCHEMBL91579 | 0.77 | PDPK1 (0.55) | KIF11FGFR1 | |
| SCHEMBL10189221 | 0.77 | KIF11 (0.47) | GSK3BMAP2K4KIF11FGFR1GRM4 | |
| SCHEMBL12292284 | 0.76 | DYRK1A (0.42) | GSK3BMAP2K4DYRK1A | |
| SCHEMBL2926142 | 0.76 | GSK3B (0.51) | GSK3BMAP2K4FGFR1DYRK1A | |
| SCHEMBL31032803 | 0.76 | MAP2K4 (0.62) | GSK3BMAP2K4 | |
| SCHEMBL2261204 | 0.76 | DYRK1A (0.65) | GSK3BMAP2K4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205507-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| US-7989461-B2 | Substituted quinazolinamine compounds for the treatment of cancer | AMGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | GSK3B 229/4885MAP2K4 70/4885KIF11 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.